Clinical Safety Assessments Need Formal Protocols, FDA Says; Guidance On "Synthesis" Possible
Executive Summary
To obtain information suitable for regulatory decision-making on a drug's safety, FDA expects the assessment of data across clinical trials to be based on a formal protocol that specifies the rules for collecting, analyzing and reporting the information.